A few days after a Cerebral Vascular Accident, the patient's family asks the nurse if tissue plasminogen activator (tPA) is a drug therapy option now. The nurse's response based on the knowledge that this drug must be used within:

A. Withhold the next dose and notify the physician:

Withholding the next dose of the cholinergic agent is the appropriate immediate action because the presence of inspiratory and expiratory wheezing bilaterally suggests bronchoconstriction or bronchospasm, which can be a serious adverse reaction to the medication. Notifying the physician promptly allows for further assessment and management of the patient's respiratory symptoms. The physician may need to adjust the medication regimen, order diagnostic tests, or provide treatment for bronchoconstriction.

B. Give the next dose:

Administering the next dose of the cholinergic agent could worsen the patient's respiratory symptoms and exacerbate bronchoconstriction. This action is contraindicated in the presence of wheezing, as it may further compromise the patient's respiratory function.

C. Assess heart rate:

While assessing heart rate is an important aspect of patient assessment, it is not the priority in this scenario. The priority is to address the respiratory distress and potential bronchoconstriction associated with the cholinergic agent. Wheezing is a respiratory symptom that suggests airway obstruction, and immediate intervention is necessary to ensure adequate oxygenation and ventilation.

D. Assess blood pressure:

Similarly, while assessing blood pressure is important in patient care, it is not the priority in this situation. The priority is to address the respiratory distress and potential bronchoconstriction associated with the cholinergic agent. Wheezing indicates respiratory compromise, and prompt action is required to prevent further respiratory deterioration.

A.Computerized tomography angiography (CTA)

This is a likely diagnostic test that the provider may prescribe. CTA uses computed tomography (CT) imaging to visualize the blood vessels in the brain and neck. It can help identify areas of stenosis, occlusion, or other abnormalities in the blood vessels that may contribute to the TIA symptoms.

B. Complete blood count (CBC)

A complete blood count (CBC) is a routine laboratory test that assesses various components of blood, such as red blood cells, white blood cells, and platelets. While it may not be specific to diagnosing a transient ischemic attack (TIA), it can help evaluate for underlying conditions such as anemia or thrombocytosis that could contribute to TIA symptoms or increase the risk of stroke.

C. Prothrombin time (PT)

Prothrombin time (PT) is a laboratory test that evaluates the clotting ability of blood and is typically used to monitor anticoagulant therapy. While abnormal coagulation parameters may be associated with certain conditions that predispose to TIA (such as atrial fibrillation), PT alone is not a specific diagnostic test for TIA.

D. Transesophageal echocardiogram (TEE)

This is another possible diagnostic test that the provider may prescribe. TEE is a specialized echocardiogram that provides detailed images of the heart structures by inserting an ultrasound probe